EFS
NBIX icon

Essex Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

Essex Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Sell
1,399
-439
-24% -$65.1K 0.01% 730
2026
Q1 		$242K Buy
1,838
+302
+20% +$40.1K 0.01% 686
2025
Q4 		$218K Buy
+1,536
New +$223K 0.01% 727

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Essex Financial Services's NBIX Position: Q2 2026 in Review

Essex Financial Services reduced its Neurocrine Biosciences (NBIX) stake by 24% in Q2 2026, selling an estimated $65.1K and leaving 1,399 shares worth $236K. The position accounts for 0.01% of the portfolio, ranked #730.

Essex Financial Services first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. The position peaked at $242K in Q1 2026. 526 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Essex Financial Services held 1,399 shares of Neurocrine Biosciences worth $236K as of Q2 2026.
  • Essex Financial Services sold 439 Neurocrine Biosciences shares in Q2 2026, an estimated $65.1K.
  • Neurocrine Biosciences made up 0.01% of Essex Financial Services's portfolio in Q2 2026, its #730 holding.
  • Essex Financial Services first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Essex Financial Services's Neurocrine Biosciences position peaked at $242K in Q1 2026.
  • 526 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Essex Financial Services's 13F filing for Q2 2026, filed 10 Aug 2026.